Massar Capital Management LP Buys Shares of 74,339 ADMA Biologics, Inc. (NASDAQ:ADMA)

Massar Capital Management LP bought a new stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 74,339 shares of the biotechnology company's stock, valued at approximately $1,275,000. ADMA Biologics makes up approximately 1.4% of Massar Capital Management LP's portfolio, making the stock its 25th largest position.

Several other institutional investors also recently bought and sold shares of ADMA. Hsbc Holdings PLC grew its stake in shares of ADMA Biologics by 38.0% in the 4th quarter. Hsbc Holdings PLC now owns 29,736 shares of the biotechnology company's stock worth $511,000 after buying an additional 8,186 shares in the last quarter. B Group Inc. bought a new stake in shares of ADMA Biologics during the fourth quarter valued at approximately $39,231,000. State of Tennessee Department of Treasury raised its stake in ADMA Biologics by 25.4% in the fourth quarter. State of Tennessee Department of Treasury now owns 105,482 shares of the biotechnology company's stock worth $1,809,000 after buying an additional 21,367 shares in the last quarter. Teachers Retirement System of The State of Kentucky raised its stake in ADMA Biologics by 37.6% in the fourth quarter. Teachers Retirement System of The State of Kentucky now owns 72,100 shares of the biotechnology company's stock worth $1,237,000 after buying an additional 19,708 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its stake in ADMA Biologics by 1,029.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 39,236 shares of the biotechnology company's stock worth $673,000 after buying an additional 35,763 shares in the last quarter. 75.68% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald reissued an "overweight" rating and set a $25.00 price objective on shares of ADMA Biologics in a report on Tuesday, March 4th.

ADMA Biologics Trading Down 2.1 %

Shares of ADMA Biologics stock traded down $0.47 during trading hours on Friday, hitting $21.86. The company's stock had a trading volume of 2,611,436 shares, compared to its average volume of 3,644,854. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. The stock has a market cap of $5.19 billion, a price-to-earnings ratio of 78.07 and a beta of 0.53. ADMA Biologics, Inc. has a twelve month low of $6.49 and a twelve month high of $23.64. The firm has a fifty day moving average of $18.80 and a 200-day moving average of $18.27.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.